Scholar Rock Holding buy Cantor Fitzgerald
Start price
17.07.25
/
50%
€35.00
Target price
17.07.26
-
Performance (%)
29.89%
End price
18.07.26
€45.46
Summary
This prediction ended on 18.07.26 with a price of €45.46. The prediction had a final performance of 29.89%. Cantor_Fitzgerald has a follow-up prediction for Scholar Rock Holding where he still thinks Scholar Rock Holding is a Buy. Cantor_Fitzgerald has 50% into this predictionScholar Rock is a clinical-stage biopharmaceutical company that engages in the discovery and development of innovative medicines to treat serious diseases in patients that currently have limited or no treatment options. Their pipeline consists of a number of product candidates that target growth factor signaling pathways within the human body. These products hold potential for the treatment of multiple diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock, which trades under the symbol SRRK, is listed on the NASDAQ stock exchange.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Scholar Rock Holding | -7.456% | -7.456% | 26.879% |
| iShares Core DAX® | 2,33 % | 1,01 % | 10,41 % |
| iShares Nasdaq 100 | 1,37 % | -3,61 % | 27,40 % |
| iShares Nikkei 225® | 2,44 % | -7,46 % | 49,84 % |
| iShares S&P 500 | 1,26 % | 0,68 % | 23,67 % |
Comments by Cantor_Fitzgerald for this prediction
In the thread Scholar Rock Holding diskutieren
Scholar Rock Holding Corporation (NASDAQ: SRRK) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for SRRK provided by MarketBeat
In the thread Trading Scholar Rock Holding
Die von Cantor_Fitzgerald gewählte maximale Laufzeit wurde überschritten